Volume 25, Issue 6 e13998
ORIGINAL ARTICLE

Antithymocyte globulin induction therapy and myocardial complement deposition in pediatric heart transplantation

Stephanie Ghaleb

Corresponding Author

Stephanie Ghaleb

The Heart Institute, Cincinnati Children’s Medical Center, Cincinnati, OH, USA

Correspondence

Stephanie Ghaleb, University of Mississippi Medical Center, 2500 N State St, Jackson, MS 39216, USA.

Email: [email protected]

Search for more papers by this author
Samuel G. Wittekind

Samuel G. Wittekind

The Heart Institute, Cincinnati Children’s Medical Center, Cincinnati, OH, USA

Search for more papers by this author
Hugo Martinez

Hugo Martinez

The Heart Institute, Cincinnati Children’s Medical Center, Cincinnati, OH, USA

Search for more papers by this author
Jennifer Kasten

Jennifer Kasten

Department of Pathology, Cincinnati Children’s Medical Center, Cincinnati, OH, USA

Search for more papers by this author
Zhiqian Gao

Zhiqian Gao

The Heart Institute, Cincinnati Children’s Medical Center, Cincinnati, OH, USA

Search for more papers by this author
Tricia Hengehold

Tricia Hengehold

University of Cincinnati College of Medicine, Cincinnati, OH, USA

Search for more papers by this author
Clifford Chin

Clifford Chin

The Heart Institute, Cincinnati Children’s Medical Center, Cincinnati, OH, USA

Search for more papers by this author
First published: 11 March 2021

Abstract

Background

Antithymocyte globulin (ATG) consists of polyclonal antibodies directed primarily against human T lymphocytes but may contain antibodies with affinity for other tissues in the transplanted organ, resulting in complement (C4d) deposition. This phenomenon has been demonstrated in endomyocardial biopsies (EMBs) of adult cardiac transplants. We examined the relationship of induction immunosuppression with ATG and C4d deposition in EMB of pediatric cardiac transplants.

Methods

Results of C4d immunohistochemistry were available from all EMB of patients transplanted at our center between June 2012 and April 2018 (n = 48) who received induction immunosuppression with either ATG (n = 20) or basiliximab (n = 28) as the standard of care.

Results

C4d deposition in the first year post–heart transplant was more commonly seen among patients who received ATG induction (20% of EMBs in ATG group vs 1% of EMBs in basiliximab group; p < .0001). C4d deposition related to ATG was observed early post-transplant (50% ATG vs 0% basiliximab on first EMB; p < .0001 and 35% ATG vs 0% basiliximab on the second EMB; p = .0012). While this difference waned by the third EMB (5% ATG vs 0% basiliximab; p = .41), positive C4d staining persisted to the sixth EMB in the ATG group only (6%).

Conclusion

C4d deposition is common on EMB up to 1 year post–pediatric cardiac transplant following ATG induction. This high rate of positive C4d staining in the absence of histologic AMR after ATG induction therapy must be accounted for in making clinical decisions regarding cardiac allograft rejection diagnosis and treatment.

CONFLICT OF INTEREST

None of the authors has a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflicts of interest to disclose. The other authors report no conflicts of interest in this study.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.